“…METHODS: We used the Veradigm PINNACLE outpatient registry linked to Symphony Health’s Integrated Dataverse data from July 1, 2013, to September 30, 2017. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: Treatment-naïve PLWH with BMI ≥25 kg/m(2) who initiated DRV/c/FTC/TAF or DTG + FTC/TAF (index date) had ≥12 months of baseline observation and ≥1 weight/BMI measurement in baseline and post-index periods in the Symphony Health IDV(®) database (07/17/2017–12/31/2021) were included. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Objectives: To describe demographic and clinical characteristics of insured patients with HIV-1 in the United States initiating darunavir/​cobicistat/​emtricitabine/​tenofovir alafenamide (DRV/c/FTC/TAF) or bictegravir/FTC/TAF (BIC/FTC/TAF), assess the differences in weight and body mass index (BMI) change between cohorts up to one year after treatment initiation, and identify the predictors of weight gain associated with each treatment. Methods: The Symphony Health, IDV® database (July 17, 2017 – September 30, 2019) was used to identify treatment naïve or virologically suppressed stable switchers who initiated DRV/c/FTC/TAF or BIC/FTC/TAF (index date) on or after July 17, 2018, were ≥18 years of age on the index date, and had ≥12 months of continuous clinical activity pre-index (baseline period). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort analysis used data from the Symphony Health claims data set. This national medical and prescription data set comprises 280 million patients and 1.8 million prescribers in the US. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: A longitudinal, retrospective matched-cohort study was conducted of patients initiating adalimumab between January 2015 and February 2016 with or without enrolling in the PSP, using patient-level data from the HUMIRA Complete PSP linked with Symphony Health claims. The sample included adult, commercially insured patients diagnosed with an indicated disease who were biologic-naive and had data available for ≥ 6 months before and ≥ 12 months after initiating adalimumab. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS AND FINDINGS: We analyzed prescription drug claims for individuals prescribed PrEP in the Integrated Dataverse (IDV) from Symphony Health for the period of September 2015 to August 2016 to describe PrEP patients, prescribers, relative uptake, and payment methods in the US. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used retail pharmacy claims from May 2019 to June 2021 from the Symphony Health database, which includes 92% of US retail pharmacy claims, with race and ethnicity data spanning all insurance status and payer categories. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: ABOVE was a retrospective US cohort study using Symphony Health Solutions Integrated Dataverse administrative claims database from 01/01/2020 to 12/31/2022. …”
Enlace del recurso
Enlace del recurso

“…METHODS: This retrospective, longitudinal cohort analysis used Symphony Health’s Integrated Dataverse (IDV®) claims data to identify patients aged ≥ 18 years with a diagnosis of FS who had a new prescription for ESL between April 2015 and June 2018. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso